United Advisor Group’s Regeneron Pharmaceuticals REGN Stock Holding History

United Advisor Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$209K	Hold	335	–	–	0.02%	510
2026 Q1	$259K	Buy	335 +4	+1%	+$3.06K	0.03%	426
2025 Q4	$256K	Sell	331 -130	-28%	-$88.3K	0.03%	414
2025 Q3	$259K	Buy	461 +76	+20%	+$43K	0.03%	396
2025 Q2	$202K	Buy	385 +4	+1%	+$2.23K	0.03%	377
2025 Q1	$242K	Sell	381 -74	-16%	-$50.9K	0.05%	308
2024 Q4	$324K	Sell	455 -94	-17%	-$78.9K	0.06%	283
2024 Q3	$577K	Buy	549 +224	+69%	+$249K	0.13%	161
2024 Q2	$342K	Buy	325 +30	+10%	+$29.1K	0.11%	185
2024 Q1	$284K	Buy	+295	New	+$281K	0.11%	168

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

United Advisor Group's REGN Position: Q2 2026 in Review

United Advisor Group held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 335 shares worth $209K. The position accounts for 0.02% of the portfolio, ranked #510.

United Advisor Group first reported a position in REGN in Q1 2024 and has held it in 10 quarters since. The position peaked at $577K in Q3 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

United Advisor Group held 335 shares of Regeneron Pharmaceuticals worth $209K as of Q2 2026.
United Advisor Group left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.02% of United Advisor Group's portfolio in Q2 2026, its #510 holding.
United Advisor Group first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
United Advisor Group's Regeneron Pharmaceuticals position peaked at $577K in Q3 2024.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on United Advisor Group's 13F filing for Q2 2026, filed 29 Jul 2026.